Last reviewed · How we verify
Corneal abrasion
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Cortisporin · Pfizer
- Lotemax · Bausch Health
- Tobi · Novartis
- Fml · AbbVie
- Cortifoam · Pfizer
- Medrifar · AbbVie
- Cortone
- Lotemax · Tufts Medical Center
- Decadron · Generic (originally Merck)
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
- Cortisporin · Pfizer
- Cortef · Generic (originally Merck/Upjohn)
- Cortisporin · Pfizer
- Flarex · Harrow Health
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Corneal abrasion patent landscape — cliff calendar, originator estates, attackable patents
- Corneal abrasion treatment landscape brief
- Corneal abrasion treatment updates RSS
Frequently asked questions about Corneal abrasion
What drugs treat Corneal abrasion?
Tracked treatments include Ramycin, Cortisporin, Lotemax, Tobi, Fml, Cortifoam, Medrifar, Cortone.
What is the treatment for Corneal abrasion?
Standard treatment for Corneal abrasion includes Ramycin, Cortisporin, Lotemax, Tobi, Fml. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Corneal abrasion patent cliff · Corneal abrasion CI report
- Treatment: Ramycin
- Treatment: Cortisporin · Pfizer
- Treatment: Lotemax · Bausch Health
- Treatment: Tobi · Novartis
- Treatment: Fml · AbbVie
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing